Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Cytel's cell adhesion inhibitor trial discontinued

June 7, 1996

First chronotherapeutic agent for hypertension and angina now avaliable in U.S.

June 7, 1996

Warner-Lambert reveals indole endothelin antagonists

June 7, 1996

Taisho researchers reveal cGMP-dependent phosphodiesterase (PDE V) inhibitors

May 31, 1996

Phase II clinical trial on Gensia's second-generation adenosine-regulating agent commence

May 31, 1996

Gene transfer as treatment for myocardial ischemia

May 31, 1996

Valsartan approved in Germany

May 31, 1996

Endothelin antagonists revealed by Fujisawa

May 31, 1996

FDA to discuss ProAmatine application

May 24, 1996

Na+/K+-ATPase inhibitors disclosed by Sigma-Tau

May 24, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...